Subscribe
shutterstock_2252763175_somyuzu
2 January 2024FeaturesBig PharmaManita Rawat and Alexander Stein

2024 forecast: AI, patent eligibility and Fintiv

A few key items related to patents in the US are at the forefront of shaping our patent laws in 2024.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Edwards Lifesciences revives Fintiv challenge
14 March 2023   Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.
Americas
USPTO aims to fend off Fintiv challenge at SCOTUS
14 November 2023   Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.
Biotechnology
The patentability of AI-related inventions
25 January 2024   Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Edwards Lifesciences revives Fintiv challenge
14 March 2023   Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.
Americas
USPTO aims to fend off Fintiv challenge at SCOTUS
14 November 2023   Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.
Biotechnology
The patentability of AI-related inventions
25 January 2024   Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper.

More on this story

Americas
Edwards Lifesciences revives Fintiv challenge
14 March 2023   Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.
Americas
USPTO aims to fend off Fintiv challenge at SCOTUS
14 November 2023   Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.
Biotechnology
The patentability of AI-related inventions
25 January 2024   Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
Pfizer infringed haemophilia therapy patent, says court
Apple wins just $250 in Masimo smartwatch clash
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar